Hematopathologic Correlates of CAR T-Cell Therapy.
B-ALL
CAR T-cell therapy
CD19
Hematopathology
Immunotherapy
Tisagenlecleucel
Journal
Clinics in laboratory medicine
ISSN: 1557-9832
Titre abrégé: Clin Lab Med
Pays: United States
ID NLM: 8100174
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
CD19-targeting chimeric antigen rector (CAR) T-cell products are used for the treatment of relapsed/refractory B-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma. The success of CD19-CAR-T cells has led to the investigation of CAR T-cell products targeting different antigens in other hematological malignancies and solid tumors. Clinical laboratories play an important role in the manufacture, distribution, and monitoring of CAR T-cell therapy. Hence, it is important for laboratory professionals to be cognizant of clinicopathologic aspects of CAR T-cell therapy.
Identifiants
pubmed: 34304768
pii: S0272-2712(21)00012-3
doi: 10.1016/j.cll.2021.03.012
pii:
doi:
Substances chimiques
Antigens, CD19
0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-339Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.